Last reviewed · How we verify
NCT03817632
Orthopilot Elite Post-Market Clinical Follow-Up
trial testing Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1 in Degenerative Osteoarthritis in 217 participants. Completed in 29 October 2022.
30 June 2022
Quick facts
| Lead sponsor | Aesculap AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 217 |
| Start date | 1 July 2019 |
| Primary completion | 30 June 2022 |
| Estimated completion | 29 October 2022 |
| Sites | 3 locations across Germany |
Drugs / interventions tested
- Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1
- Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
Conditions studied
- Degenerative Osteoarthritis — all drugs for Degenerative Osteoarthritis →
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
- Posttraumatic Arthropathy — all drugs for Posttraumatic Arthropathy →
- Instability, Joint — all drugs for Instability, Joint →
Sponsor
Aesculap AG — full company profile →
Who can join
Adults 18 to 80, any sex, with Degenerative Osteoarthritis or Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, multicenter, observational, comparative clinical trial on the equivalence of two different OrthoPilot® navigation system generations applied for computer-assisted total knee arthroplasty
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03817632
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Degenerative Osteoarthritis
Currently open trials in the same condition.
- NCT03291470 — Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee · Phase 3 · active not recruiting
- NCT03203330 — A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee · Phase 3 · active not recruiting
Other Aesculap AG trials
Trials by the same sponsor.
- NCT05441618 — Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant® · completed
- NCT05944081 — Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device · withdrawn
- NCT06298500 — Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair · completed
- NCT06055946 — Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatect · completed
- NCT05182320 — Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03817632 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aesculap AG
- Last refreshed: 17 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817632.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing